[email protected] +44 20 8123 2220 (UK) +1 732 587 5005 (US) Contact Us | FAQ |

New Report on Partnering Terms & Agreements in Diagnostics by CurrentPartnering

02 Feb 2012 • by Natalie Aster

The majority of deals in the diagnostics are development stage whereby the licensee obtains a right or an option right to license the licensors diagnostic technology or product candidates. These deals tend to be multicomponent, starting with collaborative R&D, and commercialization of outcomes.

There are also a significant number of late stage and marketed diagnostic product partnering deals announced each year, where the licensor is seeking a partner to manufacture, supply, market, distribute or co-promote the product to enhance market coverage. This is particularly prevalent in diagnostics as partners often rely on diagnostic specialists to manufacture, distribute and supply products to the market.

According to the report “Diagnostics Partnering Terms and Agreements” CurrentPartnering, a relatively unique characteristic of diagnostic partnering is the amount of acquisition activity relative to the total number of partnering deals, especially in recent years. It would appear that many biopharma companies have sought to acquire rather than partner diagnostic intellectual property, providing access to ready-made development expertise.

Another unique characteristic of diagnostic partnering is the number of litigation and settlement agreements relative to the total number of partnering deals. This report provides details of the latest diagnostics agreements announced in the healthcare sectors.

The report provides a detailed understanding and analysis of how and why companies enter diagnostic partnering deals. It contains a comprehensive listing of all diagnostics partnering deals announced since January 2007, including financial terms where available, including over 2,900 links to online deal records of actual diagnostics partnering deals as disclosed by the deal parties. In addition, where available, records include contract documents as submitted to the Securities Exchange Commission by companies and their partners.

Contract documents provide the answers to numerous questions about a prospective partner’s flexibility on a wide range of important issues, many of which will have a significant impact on each party’s ability to derive value from the deal.

Report Details:

Diagnostics Partnering Terms and Agreements
Published: February 2012
Pages: 1350
Price: US$ 2.695,00

New report provides the reader with the following key benefits:

  • In-depth understanding of diagnostic deal trends since 2007
  • Analysis of the structure of diagnostic agreements with numerous real life case studies
  • Comprehensive access to over 2,900 actual diagnostic contracts entered into by the world’s biopharma companies
  • Detailed access to actual diagnostic contracts enter into by the leading fifty bigpharma companies
  • Insight into the terms included in a diagnostic agreement, together with real world clause examples
  • Understand the key deal terms companies have agreed in previous deals
  • Undertake due diligence to assess suitability of your proposed deal terms for partner companies

More information can be found in the report “Diagnostics Partnering Terms and Agreements” by CurrentPartnering.

To order the report or ask for sample pages contact [email protected]


MarketPublishers, Ltd.
Tanya Rezler
Tel: +44 208 144 6009
Fax: +44 207 900 3970
[email protected]

Analytics & News

Weekly Digest